Immune Modulation

Our approach to advancing next-generation treatments for autoimmune diseases and inflammation is based on regulation of T cells. Many subtypes of T cells, with their unique characteristics and functions, are known to mediate Th1 and Th2 type inflammatory diseases. By modulating the functions of each of these cell populations, it is possible to treat diseases with a high degree of specificity and to avoid unwanted side-effects.

CONNECT has built a drug discovery platform based on the modulation of T cell functions. In this platform, potential drug candidates are screened with high-throughput to identify leads that effectively regulate certain cell populations.

CBP-307 is such a subpopulation-specific T cell immune modulator. It activates and induces internalization of S1P1, a receptor expressed the native and central memory T cells. In this process, the drug prevents migration out of lymph nodes and reduces the entry of these T cells into the inflamed tissues. The pathway CBP-307 modulates is the Th1 pathway, associated with many autoimmune diseases.

CBP-201 is another immune modulator that regulates certain populations of T cells. The antibody binds IL-4Ra, blocking the signaling of both IL-4 and IL-13, two important and functionally overlapping cytokines that stimulate the Th2 pathway. CBP-201 is expected to treat Th2 type diseases such as asthma and atopic dermatitis without affecting the Th1 pathway, thereby avoiding unwanted sides due to global immune suppression.


TEL/FAX: 0512-53577866

E-MAIL: qchang@connectpharm.com

ADD: Science and Technology Park, East R&D Building , 3rd Floor , 6 Beijing West Road, Taichang, Jiangsu, China 215400

Copyright: Suzhou Connect Biopharmaceuticals, Ltd.

Technical support: Epower